PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6260350

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
EURO-CELTIQUE S.A.	09/13/2019

RECEIVING PARTY DATA

Name:	PURDUE PHARMA L.P.
Street Address:	ONE STAMFORD FORUM
Internal Address:	201 TRESSER BOULEVARD
City:	STAMFORD
State/Country:	CONNECTICUT
Postal Code:	06901

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	16763185

CORRESPONDENCE DATA

Fax Number: (202)371-2540

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 2023712600

Email: karenm@sternekessler.com,yparker@sternekessler.com

Correspondent Name: STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.

Address Line 1: 1100 NEW YORK AVENUE, NW Address Line 4: WASHINGTON, D.C. 20005

ATTORNEY DOCKET NUMBER:	1861.4270001/JMC/KRM	
NAME OF SUBMITTER:	KAREN R. MARKOWICZ	
SIGNATURE:	/Karen R. Markowicz #36,351/	
DATE SIGNED:	08/20/2020	

Total Attachments: 7

source=2020-08-19-Assignment-EUSA-PPLP-2019-1861-4270001#page1.tif source=2020-08-19-Assignment-EUSA-PPLP-2019-1861-4270001#page2.tif source=2020-08-19-Assignment-EUSA-PPLP-2019-1861-4270001#page3.tif source=2020-08-19-Assignment-EUSA-PPLP-2019-1861-4270001#page4.tif source=2020-08-19-Assignment-EUSA-PPLP-2019-1861-4270001#page5.tif

PATENT 506213607 REEL: 053553 FRAME: 0817

source=2020-08-19-Assignment-EUSA-PPLP-2019-1861-4270001#page6.tif source=2020-08-19-Assignment-EUSA-PPLP-2019-1861-4270001#page7.tif

PATENT REEL: 053553 FRAME: 0818

PATENT ASSIGNMENT AGREEMENT

THIS PATENT ASSIGNMENT AGREEMENT (this "Assignment"), effective as of September 13, 2019 (the "Effective Date"), is by and between EURO-CELTIQUE S.A., a Luxembourg company with its registered office at 1, rue Jean Piret, 2350 Luxembourg, Luxembourg ("Assignor") and PURDUE PHARMA L.P., a Delaware limited partnership whose principal place of business is at One Stamford Forum, 201 Tresser Boulevard, Stamford, Connecticut 06901, United States ("Assignee"). Each of Assignor and Assignee may be individually referred to herein as a "Party" and collectively as the "Parties".

WITNESSETH:

WHEREAS, Assignor is a registered owner of the Assigned Patent Rights in the Territory (as defined below) and Assignor desires to assign, transfer, convey and deliver to Assignee all of Assignor's right, title and interest in, to and under such Assigned Patent Rights in the Territory.

NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which is hereby acknowledged, the Parties, intending to be legally bound, hereby agree as follows:

- 1. <u>Definitions</u>. As used in this Assignment, the following terms have the following meanings:
- a. "Assigned Patent Rights" means (i) the patents and patent applications set forth on Schedule 1, (ii) any and all divisionals, continuations, continuations-in-part, reissues, extensions, reexaminations and equivalents of any of the foregoing in the Territory, (iii) the right to claim priority from and to prosecute and obtain the grant of any patent to any of the foregoing in the Territory, and (iv) any and all rights in the Territory in the inventions disclosed in any of the foregoing.
- b. "<u>Territory</u>" means the United States of America, its districts, territories, possessions and commonwealths, including the Commonwealth of Puerto Rico.
- 2. <u>Assignment</u>. Assignor hereby irrevocably assigns, transfers, conveys and delivers to Assignee (i) all of its right, title and interest in, to and under all Assigned Patent Rights in the Territory, together with all goodwill in the Territory associated with the foregoing, in each case to be held and enjoyed by Assignee as fully and entirely as the same would have been held and enjoyed by Assignor if this assignment had not been made, (ii) all rights to sue, claim and recover for past, present and future infringement, misappropriation, dilution or other violation of any Assigned Patent Rights in the Territory, and (iii) all income, royalties, damages and payments now or hereafter due or payable with respect to any of the foregoing.
- 3. <u>Further Assurances: Power of Attorney</u>. Assignor shall, upon the reasonable request by Assignee, execute all other documents and take all actions as may be necessary or

PATENT REEL: 050**553** FRAME: 08**02** desirable to enable Assignee to prosecute, perfect, enforce, defend, register and/or record its right, title and interest in, to and under the Assigned Patent Rights, in each case, without further compensation but at the expense of Assignee. In the event that Assignor fails to execute any such document or take any such action as set forth in the preceding sentence, Assignor hereby designates Assignee as Assignor's agent, and hereby grants to Assignee a power of attorney with full power of substitution, which power of attorney shall be deemed coupled with an interest, for the purpose of executing such documents or taking such actions.

- 4. <u>Authorization to Record</u>. Assignor hereby authorizes and requests the officials of the United States Patent and Trademark Office to record and register Assignee as assignee and owner of all right, title and interest in, to and under the Assigned Patent Rights. Assignor hereby authorizes and requests the Commissioner of Patents and Trademarks and any other granting authority in the Territory to issue any Letters Patent resulting from any of the Assigned Patent Rights to Assignee.
- 5. <u>Governing Law; Successors and Assigns</u>. This Assignment shall be governed by, and construed in accordance with, the laws of the State of New York without regard to the choice of law principles thereof. This Assignment is binding upon, and inures to the benefit of, the Parties and their respective successors and assigns.
- 6. Amendments and Waivers. Any provision of this Assignment may be amended or waived if, but only if, such amendment or waiver is in writing and is signed, in the case of an amendment, by each Party, or in the case of a waiver, by the Party against whom the waiver is to be effective. No failure or delay by either Party in exercising any right, power or privilege hereunder shall operate as a waiver thereof nor shall any single or partial exercise thereof preclude any other or further exercise thereof or the exercise of any other right, power or privilege.
- 7. <u>Counterparts</u>. This Assignment may be signed in any number of counterparts, each of which shall be an original, with the same effect as if the signatures thereto and hereto were upon the same instrument. A signed copy of this Assignment delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Assignment.
- 8. <u>Entire Agreement</u>. This Assignment constitutes the entire agreement between the Parties and supersedes and extinguishes all previous agreements, promises, assurances, warranties, representations and understandings between them, whether written or oral, to the extent relating to the subject matter of this Assignment.

[SIGNATURE PAGE FOLLOWS]

2

IN WITNESS WHEREOF, the Parties, through their authorized representatives, have caused this Assignment to be duly executed and delivered as of the Effective Date.

EURO-CELTIQUE S.A.

By:

Name: Ian McClatchey

Title: Manager

STATE OF NEW YORK) ss COUNTY OF NEW YORK)

On the 13th day of September, 2019, before me personally came Ian McClatchey, who is personally known to me on the basis of satisfactory evidence to be the individual whose name is subscribed to the within instrument and did depose and say to me that he or she executed the same in his or her capacity as Manager of Euro-Celtique S.A., the entity described in and which executed the foregoing instrument, and that he or she executed and delivered said instrument pursuant to authority given by the board of directors of such entity (or other applicable authority of such entity).

(PLACE STAMP AND SEAL ABOVE)

JUSTINE C. CARR
NOTARY PUBLIC, State of New York
No. 01CA6264057
Qualified in New York County

Commission Expires June 25, 20 2

[Signature Page to Patent Assignment Agreement]

PURDUE PHARMA L.P.

By:


Name: Philip C. Strassburger

Title:

SVP, IP Strategy & Litigation

STATE OF CONECLICUT) so Shunford

On the May of Strike May before me personally came be the individual whose name is subscribed to the within instrument and did depose and say to me that he or she executed the same in his or her capacity as MANAL, the entity described in and which executed the foregoing instrument, and that he or she executed and delivered said instrument pursuant to authority given by the board of directors of such entity (or other applicable authority of such entity).



Notary Public

(PLACE STAMP AND SEAL ABOVE)

REEL: 050**553** FRAME: 0822

Schedule 1

ASSIGNED PATENT RIGHTS

Title	Application No.	Filing Date	Patent No.
FELODIPINE TRANSDERMAL DEVICE AND METHODS	10/045,595	2001-10- 23	7,018,649
ARYL SUBSTITUTED PYRIMIDINES	09/803,659	2001-03- 12	6,867,210
AUTOMATED SYSTEM AND METHOD FOR SPECTROSCOPIC ANALYSIS	09/636,041	2000-08-	6,549,861
METHOD AND APPARATUS FOR THREE DIMENSIONAL IMAGING USING INFRARED RADIATION	09/918,239	2001-07- 30	6,965,108
SPIROINDENE AND SPIROINDANE COMPOUNDS	10/126,472	2002-04- 18	6,828,440
SPIROPYRAZOLE COMPOUNDS	10/126,506	2002-04- 18	6,635,653
AMINOPYRIDINES AND METHODS OF USING THEREOF	09/819,693	2001-03- 29	6,335,354
ARYL SUBSTITUTED PYRIMIDINES AND THE USE THEREOF	10/386,483	2003-03- 13	7,229,993
NEUROACTIVE STEROIDS OF THE ANDROSTANE AND PREGNANE SERIES	08/659,192	1996-06- 06	5,925,630
IMMEDIATE RELEASE TABLET CORES OF ACETAMINOPHEN DRUGS HAVING SUSTAINED- RELEASE COATING	09/505,935	2000-02- 14	6,210,714
IMMEDIATE RELEASE TABLET CORES OF INSOLUBLE DRUGS HAVING SUSTAINED-RELEASE COATING	09/777,466	2001-02- 06	6,387,404
ORALLY ADMINISTRABLE OPIOID FORMULATIONS HAVING EXTENDED DURATION OF EFFECT	09/891,882	2001-06- 26	6,572,885
POWDER-LAYERED ORAL DOSAGE FORMS	09/598,324	2000-06- 20	7,060,293
FORMULATIONS AND METHODS FOR PROVIDING PROLONGED LOCAL ANESTHESIA	09/342,964	1996-06- 07	6,514,516
FORMULATIONS AND METHODS FOR PROVIDING PROLONGED LOCAL ANESTHESIA	09/523,361	2000-03- 10	6,524,607

Schedule 1-1

PATENT REEL: 050**553** FRAME: 08**2**6

Title	Application No.	Filing Date	Patent No.
FORMULATIONS AND METHODS FOR PROVIDING PROLONGED LOCAL ANESTHESIA	09/523,360	2000-03- 10	6,521,259
FORMULATION FOR RESPIRATORY TRACT ADMINISTRATION	09/930,927	2001-08- 16	6,642,275
NOVEL EMOLLIENT ANTIMICROBIAL FORMULATIONS CONTAINING POVIDONE IODINE	08/582,851	1996-01- 02	5,716,611
METHODS FOR PROVIDING SAFE LOCAL ANESTHESIA	09/963,256	2001-09- 26	6,699,908
STABILIZED SUSTAINED RELEASE TRAMADOL FORMULATIONS	09/109,615	1998-07- 02	6,306,438
STABILIZED SUSTAINED RELEASE TRAMADOL FORMULATIONS	10/052,844	2001-10- 19	6,645,527
PROLONGED ANESTHESIA IN JOINTS AND BODY SPACES	09/109,324	1998-07- 02	6,248,345
PROLONGED ANESTHESIA IN JOINTS AND BODY SPACES	09/824,465	2001-04- 02	6,534,081
PURINE COMPOUNDS HAVING PDE IV INHIBITORY ACTIVITY AND METHODS OF SYNTHESIS	09/209,922	1998-12- 10	6,040,447
METHODS OF SYNTHESIZING PURINE COMPOUNDS HAVING PDE IV INHIBITORY ACTIVITY	09/210,557	1998-12- 11	6,211,367
PURINE COMPOUNDS HAVING PDE IV INHIBITORY ACTIVITY AND METHODS OF SYNTHESIS	09/209,658	1998-12- 10	6,037,470
SUBSTITUTED SEMICARBAZIDES AND THE USE THEREOF	09/601,698	1999-02- 04	6,281,211
TRIAZOSPIRO COMPOUNDS HAVING NOCICEPTIN RECEPTOR AFFINITY	09/730,938	2000-12- 06	6,686,370
TERTIARY AMINO COMPOUNDS HAVING OPIOID RECEPTOR AFFINITY	09/730,814	2000-12- 06	6,984,664
ARYL SUBSTITUTED PYRAZOLES, IMIDAZOLES, OXAZOLES, THIAZOLES AND PYRROLES, AND THE USE THEREOF	09/533,864	2000-03- 24	6,414,011
ARYL SUBSTITUTED IMIDAZOLES, OXAZOLES AND THIAZOLES AND THE USE THEREOF	10/134,697	2002-04- 30	6,737,418
NOVEL THERAPEUTIC AGENTS	U.S. 61/593,459	2012-02- 01	

Schedule 1-2

Title	Application No.	Filing Date	Patent No.
NOVEL THERAPEUTIC AGENTS	U.S. 61/678,064	2012-07- 31	
HUMANIZED ANTIBODIES TARGETING HUMAN TISSUE FACTOR	U.S. 62/591,168	2017-11- 27	